- Home
- PRME vs ATXS Comparison
PRME vs ATXS Comparison
Compare PRME & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | ATXS |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 732.4M |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PRME | ATXS |
|---|---|---|
| Price | $3.48 | $12.86 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | $6.42 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 3.8M | 979.7K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,977,000.00 | $706,000.00 |
| Revenue This Year | $111.80 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 647.13 | N/A |
| 52 Week Low | $1.11 | $3.56 |
| 52 Week High | $6.94 | $13.29 |
Technical Indicators
Market Signals| Indicator | PRME | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 54.08 |
| Support Level | $3.29 | $12.64 |
| Resistance Level | $4.12 | $13.03 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 17.12 | 44.00 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.